GIGABYTE
26.3.2020 11:02:27 CET | Business Wire | Press release
(GIGABYTE) As the new Coronavirus rages around the world, many countries have announced lockdown of cities or regions. Many enterprises have begun implementing Work-from-Home policies to protect employees from infection. For those who are already working from home, you fed-up with the performance of your old computer? As for those who have not been quarantined, are you well-prepared to work from home? As a leading laptop manufacturer, GIGABYTE now provides selection guides for different consumer groups and offers excellent discounts. With GIGABYTE’s ultra-performance laptops, not only can you work effortlessly from home, but can also enjoy binge-watching and gaming thanks to their excellent display and immersive sound effects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005025/en/
As the pandemic spreads, how to work efficiently from home as well as pass time has become the focus of many people. "In addition to laptops’ performance and image quality, what concerns people working from home includes network quality, having enough ports to connect to devices such as screens, convenience of use in every corner of the house (such as the sofa or bed), and the long battery life," says Steven Chen, VP of GIGABYTE Mobility Product Business Group.
Wireless signal too weak? Not enough ports?
GIGABYTE’s AERO and AORUS Series have taken all these concerns into account. For the wireless network coverage and communication quality issues caused by the home environment, GIGABYTE combines Killer Wireless xTend technology to turn its laptops into a wireless range extender, which extends both wired and wireless networks. The latter can even be extended to cover 90 square meters, eliminating all household notspots. Besides, both series have up to nine external ports, including audio and video transmission ones for Display, HDMI, and Thunderbolt. Want to connect to a larger screen at home? You don’t have to waste money on a bunch of adapters anymore. GIGABYTE’s laptops also feature 94Wh batteries, the high capacity of which is twice that of other products in the industry, allowing laptops to work for more than 8-9 hours in high-performance mode.
Fight the Coronavirus together! Special offers for Intel Gen9 high-performance models!
Amid the Coronavirus outbreak, GIGABYTE has launched discounts for different consumer groups, directly launching models that have received both domestic and international recognition, including European Hardware Association’s Best Notebook 2019 and Taiwan Excellence Awards. Since all the discounted laptops have Intel's ninth-generation Core i7 processor, NVIDIA RTX / GTX series graphics cards and are equipped with Windows 10, whether you are someone who has to work from home or just looking for fun, you can easily find a laptop with favorable discounts that fits your personal needs!
For creators pursuing 4K UHD of HDR400 on video/audio quality - AERO 15 OLED
The AERO 15 OLED features the AMOLED 4K UHD screen, high color saturation of HDR400 Certified, ultra-high contrast, 3mm narrow border, ultra-rich and colorful image quality, and supports 100% DCI-P3 color gamut, which is far better than ordinary LCD screens’ 40% NTSC color performance. Having acquired the TÜV Rheinland's hardware low blue light certification, the AERO 15 OLED can reduce harmful blue light by more than 10% compared with ordinary screens, and protect eyes from long-hours of creative work and binge-watching. With the only X-Rite Pantone certified screen in the industry, each panel of the AERO series undergoes independent color correction, allowing its screen color to match the accuracy of the Pantone Matching System!
For people focusing on both business and entertainment – AERO 15 Classic
With a sharp and appealing appearance, the business-like AERO 15 Classic features a thickness of 1.8cm and a weight of 2.0 kg, allowing high portability for working outside once the pandemic ends. Moreover, the performance of NVIDIA GTX / RTX or above is also more than enough to play games. The AERO 15 Classic comes in various panel options, such as the 4K UHD or 144Hz/240Hz gaming monitors, allowing you to enjoy a 4K high image quality or a high refresh rate above 144Hz and to play games without stuttering. It also features X-Rite Pantone certified screens with each panel undergoing independent color correction.
For real hardcore gamers – AORUS 15
The AORUS 15 is the most powerful laptop with a thickness below 2.4cm, Intel Core i7 processor, the highest NVIDIA RTX 2060 graphics card, and unique WINDFORCE Infinity cooling technology, even the waste heat generated by the CPU and GPU can be processed independently without compromising performance. Its sharp 240Hz gaming specifications feature a super high refresh rate, allowing 3A game masterpieces to run smoothly without delay or lag.
For people pursuing high storage capacity with 144Hz display - AORUS 5/7
With the super-optimal 144Hz screen rarely seen among gaming laptops of the same level, the AORUS5/7 weighs 2.15KG and has a thickness of only 23mm, allowing gamers to enjoy lightweight and portability. Its hybrid SSD+HDD drive provides both access speed and large capacity, up to 3 storage interfaces. With a capacity of up to 6TB, you can store large amounts of games or videos without the need of external hard drives.
*For more information, please visit GIGABYTE/AORUS website:
Germany (Deutsch) |
|
France (Français) |
|
Spain (Español) |
|
United Kingdom (English) |
|
Netherlands (Dutch) |
*For more photos, please download here: https://drive.google.com/open?id=1OpkPIRJ6Pc1vSTnW7IehumMRE2YcqHax
GIGABYTE also offers quantity discounts to enterprises. In addition to greater discounts, enterprises can enjoy an extended warranty. For more information, please contact: gswe@gigabyte.com
About GIGABYTE
GIGABYTE is an engineer, visionary, and leader in the world of tech that uses its hardware expertise, patented innovations, and industry leadership to create, inspire and advance. Renowned for over 30 years of award-winning excellence, GIGABYTE is a cornerstone in the HPC community, providing businesses with server and data center expertise to accelerate their success. At the forefront of evolving technology, GIGABYTE is devoted to inventing smart solutions that enable digitalization from edge to cloud, and allow customers to capture, analyze, and transform digital information into economic data that can benefit humanity and "Upgrade Your Life". Please visit https://www.gigabyte.com/ for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005025/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom